​

Akero Therapeutics Ownership | Who Owns Akero Therapeutics?

OverviewForecastRevenueFinancialsChart

Akero Therapeutics Ownership Summary

Akero Therapeutics is owned by 11.28% institutional investors, 1.41% insiders, and 87.31% retail investors. Blackrock is the largest institutional shareholder, holding 9.42% of AKRO shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 3.01% of its assets in Akero Therapeutics shares.

AKRO Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockAkero Therapeutics11.28%1.41%87.31%
SectorHealthcare Stocks 42.50%10.81%46.69%
IndustryBiotech Stocks 45.24%10.75%44.01%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock5.59M9.42%$131.06M
Janus henderson group6.03M8.69%$167.77M
General atlantic5.73M7.02%$272.25M
Blackrock funding, inc. /de5.70M6.98%$270.76M
Rtw investments, lp5.48M6.70%$260.07M
Vanguard group4.53M5.54%$214.94M
Wellington management group llp4.25M5.20%$201.88M
Deep track capital, lp4.00M4.90%$189.97M
Avoro capital advisors3.96M4.84%$187.81M
Price t rowe associates inc /md/3.81M4.66%$180.89M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Allostery investments lp22.50K15.29%$1.20M
University of wisconsin foundation328.50K13.21%$15.60M
Propel bio management228.88K10.88%$10.87M
General atlantic5.73M8.17%$272.25M
B group232.45K8.12%$11.04M
Deep track capital, lp4.00M5.30%$189.97M
Logos global management lp1.20M5.11%$56.98M
Foresite capital management vi244.90K4.49%$11.63M
Silverarc capital management643.64K4.12%$30.56M
Redmile group747.82K3.45%$35.51M

Top Buyers

HolderShares% AssetsChange
Polar capital1.06M0.24%1.06M
Deep track capital, lp4.00M5.30%958.38K
Wellington management group llp4.25M0.04%841.91K
Blackrock5.59M0.00%694.02K
Pictet asset management sa986.63K0.05%671.92K

Top Sellers

HolderShares% AssetsChange
Woodline partners lp639.60K0.14%-1.83M
Ubs group335.68K0.00%-1.69M
Point72 asset management1.66M0.13%-1.05M
Janus henderson group6.03M0.09%-1.04M
Price t rowe associates inc /md/3.81M0.02%-699.47K

New Positions

HolderShares% AssetsChangeValue
Polar capital1.06M0.24%1.06M$50.27M
Braidwell lp475.40K0.67%475.40K$22.57M
Centerbook partners lp185.56K0.44%185.56K$8.81M
Hood river capital management178.55K0.10%178.55K$8.48M
Capricorn fund managers149.20K2.38%149.20K$7.08M

Sold Out

HolderChange
Twin peaks wealth advisors-4.00
Newedge advisors-7.00
Svb wealth-8.00
Bare financial services-10.00
C m bidwell & associates-10.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202586-68.27%9,219,263-89.50%110.10%30-78.72%35-59.30%
Jun 30, 20252798.98%92,103,2386.56%1120.93%144-14.29%8978.00%
Mar 31, 202528-86.07%15,857,543-78.62%200.18%14-87.16%7-86.00%
Dec 31, 202419810.00%74,179,4721.61%1060.97%10727.38%50-12.28%
Sep 30, 202418014.65%72,997,3861.71%1050.72%858.97%577.55%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv2.41M3.01%-50.45K
Vanguard US Total Market Shares ETF1.94M2.55%2.50K
iShares Russell 2000 ETF1.68M2.11%-
US Small-Cap Growth II Equity Comp1.63M2.04%-184.44K
Janus Henderson Global Life Sciences1.44M1.80%-117.23K
Janus Henderson Global Life Sciences D1.44M1.80%-59.07K
T. Rowe Price New Horizons1.34M1.68%-285.20K
Vanguard Health Care Inv1.26M1.58%-2.40M
Janus Global Life Science AUSD1.18M1.48%-75.10K
SPDR® S&P Biotech ETF1.14M1.42%2.54K

Recent Insider Transactions

DateNameRoleActivityValue
Oct 10, 2025Cheng Andrew President and CEOSell$1.62M
Oct 07, 2025Rolph Timothy Chief Scientific OfficerSell$48.55K
Oct 07, 2025Rolph Timothy Chief Scientific OfficerSell$527.45K
Oct 01, 2025Young Jonathan Chief Operating OfficerSell$395.40K
Oct 01, 2025Young Jonathan Chief Operating OfficerSell$201.58K

Insider Transactions Trends

DateBuySell
2025 Q4-5
2025 Q3-29
2025 Q2-45
2025 Q1439
2024 Q4-31

AKRO Ownership FAQ

Who Owns Akero Therapeutics?

Akero Therapeutics shareholders are primarily institutional investors at 11.28%, followed by 1.41% insiders and 87.31% retail investors. The average institutional ownership in Akero Therapeutics's industry, Biotech Stocks , is 45.24%, which Akero Therapeutics falls below.

Who owns the most shares of Akero Therapeutics?

Akero Therapeutics’s largest shareholders are Blackrock (5.59M shares, 9.42%), Janus henderson group (6.03M shares, 8.69%), and General atlantic (5.73M shares, 7.02%). Together, they hold 25.13% of Akero Therapeutics’s total shares outstanding.

Does Blackrock own Akero Therapeutics?

Yes, BlackRock owns 9.42% of Akero Therapeutics, totaling 5.59M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 131.06M$. In the last quarter, BlackRock increased its holdings by 694.02K shares, a 14.19% change.

Who is Akero Therapeutics’s biggest shareholder by percentage of total assets invested?

Allostery investments lp is Akero Therapeutics’s biggest shareholder by percentage of total assets invested, with 15.29% of its assets in 22.5K Akero Therapeutics shares, valued at 1.2M$.

Who is the top mutual fund holder of Akero Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Akero Therapeutics shares, with 3.01% of its total shares outstanding invested in 2.41M Akero Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools